EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Curcumin in Atherogenic Dyslipidemia: Linking Preclinical Mechanistic Insights to Clinical Outcomes

Kamil Brodziński, Justyna Juszczyńska, Joanna Karbowska iD, Zdzislaw Kochan iD

Nutrients · 11.07.2026 · 18 (14) · 2279

DOI: 10.3390/nu18142279 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nutrients, online erschienen am 11.07.2026. Verfasst von Kamil Brodziński und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Nutritional Biochemistry, Department of Clinical Nutrition, Medical University of Gdansk, 80-211 Gdansk, Poland. Hauptthemen laut MEDLINE: Curcumin, Dyslipidemias, Atherosclerosis, Dietary Supplements. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Gdansk.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Atherogenic dyslipidemia is a major cardiometabolic risk factor characterized by elevated circulating triglycerides (TGs), reduced HDL-C, and increased levels of atherogenic lipoproteins. Curcumin, a polyphenolic compound considered the main bioactive component of turmeric (Curcuma longa), has attracted growing interest because of its potential lipid-modifying and anti-inflammatory properties. This scoping review aimed to evaluate evidence from randomized controlled trials (RCTs) on the efficacy of curcumin supplementation in the management of atherogenic dyslipidemia and to summarize current mechanistic evidence related to curcumin absorption, metabolism, and regulation of lipid homeostasis.

Methods

A PRISMA-ScR-guided scoping review was performed across five databases (PubMed, Scopus, Web of Science, Cochrane Library, and Embase). RCTs evaluating curcumin supplementation in atherogenic dyslipidemia or related cardiometabolic conditions were systematically identified and synthesized. Mechanistic and preclinical evidence was identified through separate topic-specific searches of PubMed, Scopus, and Web of Science, supplemented by citation searching, and was synthesized narratively.

Results

Twenty-two RCTs published between 2008 and 2025 were included. Most studies involved patients with cardiometabolic disorders, including type 2 diabetes mellitus with hyperlipidemia, metabolic syndrome, and polycystic ovary syndrome. Curcumin supplementation, administered in various formulations and dosages, showed overall favorable effects on plasma lipid profiles, particularly TGs and LDL-C, although the magnitude of these effects varied across studies. Mechanistic and preclinical evidence suggested that curcumin may modulate multiple pathways involved in lipid homeostasis, including intestinal cholesterol uptake, hepatic lipogenesis, cholesterol synthesis, fatty acid oxidation, bile acid metabolism, and reverse cholesterol transport.

Conclusions

Current evidence suggests that curcumin may improve atherogenic lipid profiles through pleiotropic effects on lipid metabolism and cholesterol homeostasis. The clinical efficacy of curcumin appears to depend substantially on formulation-related bioavailability. Despite inter-study heterogeneity, curcumin shows potential as an adjunctive strategy for the management of atherogenic dyslipidemia and associated metabolic disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CurcuminDyslipidemiasAtherosclerosisDietary SupplementsHumansRandomized Controlled Trials as TopicLipid MetabolismAnimalsLipids

Stichwörter der Autor:innen

HDL-CLDL-Catherosclerosiscurcuminlipid-loweringlipoprotein(a)nutraceuticalsphytochemicalspolyphenolstriglycerides

Substanzen

CurcuminLipids

Autor:innen und Institutionen

  • Laboratory of Nutritional Biochemistry, Department of Clinical Nutrition, Medical University of Gdansk, 80-211 Gdansk, Poland.
  • Department of Biochemistry, Medical University of Gdansk, 80-211 Gdansk, Poland.

ORCID-Profile: Joanna Karbowska, Zdzislaw Kochan

Förderung

  • Medical University of Gdansk

Zitieren

APA

Brodziński, K., Juszczyńska, J., Karbowska, J., & Kochan, Z. (2026). Curcumin in Atherogenic Dyslipidemia: Linking Preclinical Mechanistic Insights to Clinical Outcomes. Nutrients, 18(14), 2279. https://doi.org/10.3390/nu18142279

Vancouver

Brodziński K, Juszczyńska J, Karbowska J, Kochan Z. Curcumin in Atherogenic Dyslipidemia: Linking Preclinical Mechanistic Insights to Clinical Outcomes. Nutrients. 2026;18(14):2279. doi:10.3390/nu18142279

BibTeX
@article{Brodziski2026,
  author = {Brodziński, Kamil and Juszczyńska, Justyna and Karbowska, Joanna and Kochan, Zdzislaw},
  title = {Curcumin in Atherogenic Dyslipidemia: Linking Preclinical Mechanistic Insights to Clinical Outcomes},
  journal = {Nutrients},
  year = {2026},
  volume = {18},
  number = {14},
  pages = {2279},
  doi = {10.3390/nu18142279}
}
Kostenlos starten →